Eli Lilly has signed a licensing and development agreement with Camurus, under which the two parties will jointly develop long-acting insulinotropic drugs for the treatment of obesity, diabetes and other metabolic diseases based on Camurus' FluidCrystal technology. The agreement allows Eli Lilly to develop up to four proprietary drug compounds, including GIP/GLP-1 receptor agonists, GIP/glucagon/GLP-1 receptor agonists, and options including amylin receptor agonists. At the same time, according to the agreement, Camurus is eligible for potential development and sales milestone payments of up to $870 million and mid-single-digit royalties.